open access

Vol 27, No 3 (2023)
Review paper
Published online: 2023-09-04
Get Citation

Practical use of single pill combinations in the treatment of hypertension — an analysis focused on perindopril-based combinations

Aleksander Prejbisz1, Piotr Dobrowolski1, Adrian Doroszko2, Krzysztof J. Filipiak34, Andrzej Januszewicz5, Agnieszka Olszanecka6, Krzysztof Narkiewicz7, Andrzej Tykarski4, Jacek Wolf7
·
Arterial Hypertension 2023;27(3):113-132.
Affiliations
  1. Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland
  2. Clinical Department of Cardiology, Centre for Heart Diseases, Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland
  3. Institute of Clinical Science, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
  4. Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland
  5. Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
  6. First Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College, Krakow, Poland
  7. Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland

open access

Vol 27, No 3 (2023)
Position paper
Published online: 2023-09-04

Abstract

Hypertension (HTN) is a major modifiable cardiovascular risk factor. Despite availability of effective blood pressure-lowering medications, HTN remains poorly controlled. Causes of suboptimal HTN control include the asymptomatic nature of HTN, low patient compliance, inadequate knowledge regarding the sequelae of HTN, and often complex therapeutic regimen. In the current guidelines, combination therapy using single pill combinations (SPC) has been widely recommended for the treatment of HTN. In the present paper, we evaluated the usefulness of perindopril-based SPC in various clinical scenarios in everyday practice. Perindopril-based SPC, including both two- and three-drug combinations, have been marketed since 2008. Our considerations regarding the use of perindopril-based combinations both within the basic HTN management strategy and for treatment individualization are informed by not only the everyday clinical experience but also the results of numerous clinical studies, including large randomized trials. Perindopril-based SPC are characterized by a long duration of action providing stable 24-hour blood pressure control, and the wide range of perindopril-based SPC allows their use in various clinical scenarios, thus facilitating treatment individualization.

Abstract

Hypertension (HTN) is a major modifiable cardiovascular risk factor. Despite availability of effective blood pressure-lowering medications, HTN remains poorly controlled. Causes of suboptimal HTN control include the asymptomatic nature of HTN, low patient compliance, inadequate knowledge regarding the sequelae of HTN, and often complex therapeutic regimen. In the current guidelines, combination therapy using single pill combinations (SPC) has been widely recommended for the treatment of HTN. In the present paper, we evaluated the usefulness of perindopril-based SPC in various clinical scenarios in everyday practice. Perindopril-based SPC, including both two- and three-drug combinations, have been marketed since 2008. Our considerations regarding the use of perindopril-based combinations both within the basic HTN management strategy and for treatment individualization are informed by not only the everyday clinical experience but also the results of numerous clinical studies, including large randomized trials. Perindopril-based SPC are characterized by a long duration of action providing stable 24-hour blood pressure control, and the wide range of perindopril-based SPC allows their use in various clinical scenarios, thus facilitating treatment individualization.

Get Citation

Keywords

hypertension; single pill combinations; treatment initiation; treatment intensification; therapeutic regimen

About this article
Title

Practical use of single pill combinations in the treatment of hypertension — an analysis focused on perindopril-based combinations

Journal

Arterial Hypertension

Issue

Vol 27, No 3 (2023)

Article type

Review paper

Pages

113-132

Published online

2023-09-04

Page views

675

Article views/downloads

399

DOI

10.5603/ah.96726

Bibliographic record

Arterial Hypertension 2023;27(3):113-132.

Keywords

hypertension
single pill combinations
treatment initiation
treatment intensification
therapeutic regimen

Authors

Aleksander Prejbisz
Piotr Dobrowolski
Adrian Doroszko
Krzysztof J. Filipiak
Andrzej Januszewicz
Agnieszka Olszanecka
Krzysztof Narkiewicz
Andrzej Tykarski
Jacek Wolf

References (92)
  1. Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–86.
  2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021–3104.
  3. Dobrowolski P, Prejbisz A, Bozek G, et al. Use of antihypertensive combination therapy during the COVID-19 pandemic — a cross-sectional, nation-wide study . J Hypertens. 2023; 41(Suppl 3): e77–e78.
  4. Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023.
  5. Kreutz R, Dobrowolski P, Prejbisz A, et al. European Society of Hypertension COVID-19 Task Force Review. Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. J Hypertens. 2021; 39(6): 1077–1089.
  6. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439–2454.
  7. Gupta AK, Nasothimiou EG, Chang CL, et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011; 29(10): 2004–2013.
  8. Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137.
  9. Zoungas S, Chalmers J, Neal B, et al. ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014; 371(15): 1392–1406.
  10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287): 1033–1041.
  11. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829–840.
  12. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782–788.
  13. Sobngwi E, Mfeukeu-Kuate L, Kouam M, et al. Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial. J Clin Hypertens (Greenwich). 2019; 21(7): 1002–1008.
  14. Farsang C, Dézsi CA, Brzozowska-Villatte R, et al. Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies. Adv Ther. 2021; 38(1): 479–494.
  15. Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009; 9(3): 135–142.
  16. Radchenko GD, Mushtenko LO, Sirenko YM. Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial). Vasc Health Risk Manag. 2018; 14: 265–278.
  17. Glezer MG. FORSAGE Investigators. Antihypertensive Effectiveness of Perindopril Arginine and Indapamide Single-Pill Combination According to Body Mass Index: Findings from the FORSAGE Study. Cardiol Ther. 2020; 9(1): 139–152.
  18. Karpov YA. Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study. Clin Drug Investig. 2017; 37(2): 207–217.
  19. Ábrahám G, Dézsi CA. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther. 2017; 34(7): 1753–1763.
  20. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14(2): 137–145.
  21. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014; 34(10): 701–708.
  22. Tsioufis K, Douma S, Kallistratos MS, et al. Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension. Clin Drug Investig. 2019; 39(4): 385–393.
  23. Mourad JJ, Amodeo C, de Champvallins M, et al. study coordinators, investigators. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens. 2017; 35(7): 1481–1495.
  24. Mazza A, Townsend DM, Schiavon L, et al. Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. Biomed Pharmacother. 2019; 120: 109539.
  25. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010; 375(9718): 938–948.
  26. Rothwell PM, Howard SC, Dolan E, et al. ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010; 9(5): 469–480.
  27. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010; 375(9718): 895–905.
  28. Mallion JM, Chamontin B, Asmar R, et al. REASON Project. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am J Hypertens. 2004; 17(3): 245–251.
  29. Dahlöf B, Gosse P, Guéret P, et al. PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005; 23(11): 2063–2070.
  30. de Luca N, Mallion JM, O'Rourke MF, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens. 2004; 17(8): 660–667.
  31. Mogensen CE, Viberti G, Halimi S, et al. Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension. 2003; 41(5): 1063–1071.
  32. de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009; 20(4): 883–892.
  33. Heerspink HJ, Ninomiya T, Perkovic V, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010; 31(23): 2888–2896.
  34. Karpov YA, Gorbunov VM, Deev AD. Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice. High Blood Press Cardiovasc Prev. 2015; 22(4): 417–425.
  35. Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. Clin Drug Investig. 2013; 33(7): 469–476.
  36. Prejbisz A, Dobrowolski P, Januszewicz A. Kiedy możemy powiedzieć, że ciśnienie tętnicze jest skutecznie kontrolowane? Terapia. 2022; 7: 31–39.
  37. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
  38. Beckett N, Peters R, Fletcher A, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008; 358(18): 1887–1898.
  39. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25(6): 1105–1187.
  40. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290–300.
  41. Olszanecka A, Chrostowska M, Litwin M, et al. Nadciśnienie tętnicze u młodych dorosłych. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2022; 8(3): 109–138.
  42. Rajzer M, Doroszko A, Filipiak KJ, et al. Nadciśnienie tętnicze w wieku podeszłym — izolowane nadciśnienie skurczowe. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2022; 8(4): 161–181.
  43. de Luca N, Asmar RG, London GM, et al. REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens. 2004; 22(8): 1623–1630.
  44. Dahlöf B, Gosse P, Guéret P, et al. PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005; 23(11): 2063–2070.
  45. Asmar RG, London GM, O'Rourke ME, et al. REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001; 38(4): 922–926.
  46. London GM, Asmar RG, O'Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004; 43(1): 92–99.
  47. Chalmers J, Mourad JJ, Brzozowska-Villatte R, et al. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. J Hypertens. 2023; 41(3): 508–515.
  48. Peters R, Xu Y, Fitzgerald O, et al. Dementia rIsk REduCTion (DIRECT) collaboration. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022; 43(48): 4980–4990.
  49. Mareev VYu, Minina YuV, Begrambekova YuL, et al. [Therapeutic approaches to the Rational Use of trip-le combination therapy with a fixed combination of amlodipine, indapamide and perindopril arginine (TRIPLE COMBINATION) in patients with hypertension who do not control blood pressure on conventional treatment. (Description and main results of the TRIO program)]. Kardiologiia. 2020; 60(5): 1149.
  50. Kobalava ZhD, Kolesnik EL, Shavarova EK, et al. Effectiveness of indapamide/amlodipine single-pill combination in patients with isolated systolic hypertension: post-hoc analysis of the ARBALET study. BMC Cardiovasc Disord. 2022; 22(1): 85.
  51. Jadhav U, Hiremath J, Namjoshi DJ, et al. Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. PLoS One. 2014; 9(4): e92955.
  52. Rimoldi SF, Messerli FH, Chavez P, et al. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich). 2015; 17(3): 193–199.
  53. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome — a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci. 2022; 18(5): 1133–1156.
  54. Hall ME, Cohen JB, Ard JD, et al. American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2021; 78(5): e38–e50.
  55. Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015; 116(6): 991–1006.
  56. Farsang C, Dézsi CA, Brzozowska-Villatte R, et al. Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies. Adv Ther. 2021; 38(1): 479–494.
  57. Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013; 381(9866): 537–545.
  58. Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension. 2010; 55(5): 1193–1198.
  59. Visseren FLJ, Mach F, Smulders YM, et al. ESC Scientific Document Group, ESC Scientific Document Group, ESC Scientific Document Group, ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  60. Januszewicz A, Prejbisz A, Kabat M, Dobrowolski P. Vademecum diagnostyki i leczenia nadciśneinia tętniczego oraz zaburzeń lipidowych. Poradnik dla lekarza praktyka. Medycyna Praktyczna, Kraków 2023.
  61. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. 2023 Guidelines on the management of patients with diabetes — a position of Diabetes Poland. Curr Topics Diab. 2023; 3: 1–133.
  62. Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014; 63(2): 259–264.
  63. Saraste A, Barbato E, Capodanno D, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  64. Boytsov SA, Burtsev YP, Khomitskaya YV, et al. STYLE study investigators. Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study. Adv Ther. 2021; 38(6): 3299–3313.
  65. Bertrand ME, Ferrari R, Remme WJ, et al. EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010; 159(5): 795–802.
  66. Agarwal R, Sinha AD, Tu W, et al. Thiazides in advanced chronic kidney disease: time for a randomized controlled trial. Curr Opin Cardiol. 2015; 30(4): 366–372.
  67. Barizien N, Le Guen M, Russel S, et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021; 11(1): 14042.
  68. Puntmann VO, Martin S, Shchendrygina A, et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med. 2022; 28(10): 2117–2123.
  69. Ostrowska A, Prejbisz A, Dobrowolski P, et al. Short and long-term survival in patients hospitalized due to COVID-19 in relation to cardiovascular risk factors and established cardiovascular diseases: the Cor-Cardio Study. Pol Arch Intern Med. 2023(16441).
  70. Wojciechowska W, Terlecki M, Klocek M, et al. CRACoV-HHS Investigators†. Impact of Arterial Hypertension and Use of Antihypertensive Pharmacotherapy on Mortality in Patients Hospitalized due to COVID-19: The CRACoV-HHS Study. Hypertension. 2022; 79(11): 2601–2610.
  71. François B, Cahen R, Gravejat MF, et al. Do beta blockers prevent pressor responses to mental stress and physical exercise? Eur Heart J. 1984; 5(5): 348–353.
  72. Das M. Panic disorder: propranolol and behavioural therapy. BMJ. 2006; 332(7549): 1094.
  73. Hall JE, Mouton AJ, da Silva AA, et al. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Cardiovasc Res. 2021; 117(8): 1859–1876.
  74. Hsia J, Larson JC, Ockene JK, et al. Women's Health Initiative Research Group. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ. 2009; 338: b219.
  75. Gerdts E, Sudano I, Brouwers S, et al. Sex differences in arterial hypertension. Eur Heart J. 2022; 43(46): 4777–4788.
  76. Frohlich ED. Beta adrenergic blockade in the circulatory regulation of hyperkinetic states. Am J Cardiol. 1971; 27(2): 195–199.
  77. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014; 114(11): 1804–1814.
  78. Grassi G, Mark A, Esler M, et al. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015; 116(6): 976–990.
  79. Lüders S, Schrader J, Berger J, et al. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008; 26(7): 1487–1496.
  80. Doroszko A, Dobrowolski P, Prejbisz A, et al. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego i Polskiego Towarzystwa Medycyny Stylu Życia dotyczące aktywności sportowej i seksualnej u pacjentów z nadciśnieniem tętniczym. Nadciśnienie Tętnicze w Praktyce. 2023; 9(1): 1–25.
  81. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75(6): 1334–1357.
  82. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36(10): 1953–2041.
  83. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010; 55(2): 399–407.
  84. Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postępowania w nadciśnieniu tętniczym - 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2015; 1(2): 1–70.
  85. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281–1357.
  86. Syed YY, Syed YY. Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. Am J Cardiovasc Drugs. 2022; 22(2): 219–230.
  87. Filipiak KJ, Szymański F, Szmit S. (eds). Hipertensjoonkologia. Nadciśnienie tętnicze w chorobie nowotoworowej. Wydawnictwo Via Medica, Gdańsk 2018.
  88. Lyon A, López-Fernández T, Couch L, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
  89. Patel SS, Nakka S. Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer. Anticancer Agents Med Chem. 2017; 17(7): 955–960.
  90. Lódi M, Bánhegyi V, Bódi B, et al. Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. J Transl Med. 2020; 18(1): 470.
  91. Mozolevska V, Schwartz A, Cheung D, et al. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2019; 316(3): H446–H458.
  92. Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017; 35(8): 870–877.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl